Boston Scientific Corp. and its subsidiary, Guidant, will pay $30 million to settle allegations that Guidant knowingly sold defective heart devices that were implanted in Medicare patients between 2002 and 2005.
In a civil action filed by the United States Department of Justice on January 27, 2011, the DOJ alleged that Guidant knowingly sold defective implantable defibrillators. These devices are surgically implanted into patients’ chests to ...
continue reading...